ArticleBoneKEy reports2012
Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.
Article in BoneKEy reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 85 citations in OpenAlex.
- Increased Bone Resorption during Lactation in Pycnodysostosis.International journal of molecular sciences · 2021Trial
- Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial.BMC veterinary research · 2018Trial
- Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Trial
- Cathepsin K inhibition by VBX1000 alleviates canine periodontitis.Frontiers in veterinary science · 2025Article
- Proteases and Osteoporosis: A Comprehensive Review of Their Role in Bone Health.Current drug targets · 2025Review
- Bone Disease in Primary Hyperparathyroidism-Changes Occurring in Bone Metabolism and New Potential Treatment Strategies.International journal of molecular sciences · 2024Review
- Cathepsin K: The Action in and Beyond Bone.Frontiers in cell and developmental biology · 2020Review
- Cathepsin K-deficient osteocytes prevent lactation-induced bone loss and parathyroid hormone suppression.The Journal of clinical investigation · 2019Article
- Coupling factors involved in preserving bone balance.Cellular and molecular life sciences : CMLS · 2019Review
- Article
- Inhibition of cathepsin K promotes osseointegration of titanium implants in ovariectomised rats.Scientific reports · 2017Article
- High-throughput chinmedomics-based prediction of effective components and targets from herbal medicine AS1350.Scientific reports · 2016Article
- Effects of odanacatib on bone matrix mineralization in rhesus monkeys are similar to those of alendronate.Bone reports · 2016Article
- Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.Therapeutic advances in musculoskeletal disease · 2016Review
- Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells.The international journal of biochemistry & cell biology · 2016Article
- Value of rare low bone mass diseases for osteoporosis genetics.BoneKEy reports · 2016Review
- The role of osteoclast differentiation and function in skeletal homeostasis.Journal of biochemistry · 2016Review
- Odanacatib increases mineralized callus during fracture healing in a rabbit ulnar osteotomy model.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2016Article
- Review
- Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women.Therapeutic advances in musculoskeletal disease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a disease of high bone remodeling with an imbalance of bone resorption over bone formation, resulting in decreased bone mineral density and deterioration of bone microarchitecture. From the emerging understandings of the molecular and cellular regulators of bone remodeling, potential new targets for therapeutic intervention for this disease have been identified. Cathepsin K (CatK), a cysteine protease produced by osteoclasts, is the primary enzyme mediating the degradation of the demineralized bone matrix. Current genetic and pharmacological evidence from studies in multiple preclinical species have consistently demonstrated that inhibition of CatK results in the reduction of bone resorption while allowing bone formation to continue. Early results from clinical studies with several investigational CatK inhibitors indicate that the impact of CatK inhibition on bone formation is distinct from that of either the bisphosphonates or the anti-receptor activator of nuclear factor-κB ligand antibody, denosumab. Odanacatib, a highly selective, reversible and potent inhibitor of CatK, is currently in phase III clinical trials for the treatment of postmenopausal osteoporosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.